SCHEMBL7649928

SCHEMBL7649928

CO/N=C1C(=N\O)\Oc2ccccc2\1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
STK17B O94768 5/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPK1 P28482 1/20 0.33
ATM Q13315 1/20 0.33
ACHE P22303 1/20 0.33
MAPT P10636 2/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
MAPK10 P53779 1/20 0.32
PTK2B Q14289 1/20 0.32
NCOA1 Q15788 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
GSK3A P49840 3/20 0.32
GSK3B P49841 3/20 0.32
CDK5 Q00535 3/20 0.32
CDK5R1 Q15078 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7511650 1.00 MEN1 (0.35) MEN1KMT2ASTK17BKDM4EMAPK1
SCHEMBL6654635 1.00 MEN1 (0.35) MEN1KMT2ASTK17BKDM4EMAPK1
SCHEMBL16382613 1.00 MEN1 (0.35) MEN1KMT2ASTK17BKDM4EMAPK1
SCHEMBL22057240 1.00 MEN1 (0.35) MEN1KMT2ASTK17BKDM4EMAPK1
SCHEMBL31738409 1.00 MEN1 (0.35) MEN1KMT2ASTK17BKDM4EMAPK1
SCHEMBL16378826 0.85 KDM4E (0.34) STK17BKDM4EMAPK1ATMACHE
SCHEMBL18924580 0.83 KDM4E (0.33) MEN1KMT2ASTK17BKDM4EMAPK1
SCHEMBL7170811 0.82 MEN1 (0.48) MEN1KMT2ASTK17BKDM4EMAPK1
SCHEMBL5196943 0.81 TYMS (0.40) MEN1KMT2ASTK17BKDM4EMAPK1
SCHEMBL5196941 0.81 TYMS (0.40) MEN1KMT2ASTK17BKDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3303312-B1 PROCESS FOR PREPARING (E)-(5,6-DIHYDRO-1,4,2-DIOXAZINE-3-YL)(2-HYDROXYPHENYL)METHANONE O-METHYL OXIME ARYSTA LIFESCIENCE CORP (JP) 2023-07-19 EP disclosed
EP-3699178-A1 PROCESS FOR PREPARING FLUOXASTROBIN Arysta LifeScience Corporation (JP) 2020-08-26 EP disclosed
EP-3019495-B1 PROCESS FOR PREPARING FLUOXASTROBIN ARYSTA LIFESCIENCE CORP (JP) 2020-06-03 EP disclosed
US-20180148423-A1 Process for Preparing (E)-(5,6-Dihydro-1,4,2-Dioxazine-3-YL) (2-Hydroxyphenyl) Methanone O-Methyl Oxime ARYSTA LIFESCIENCE CORPORATION (JP) 2018-05-31 US disclosed
WO-2016193822-A1 PROCESS FOR PREPARING (E)-(5,6-DIHYDRO-1,4,2-DIOXAZINE-3-YL) (2-HYDROXYPHENYL) METHANONE O-METHYL OXIME ARYSTA LIFESCIENCE CORPORATION (JP) 2016-12-08 WO disclosed
US-6462205-B1 E ISOMERS ARE FORMED PREDOMINANTLY IN HIGH YIELDS BAYER AKTIENGESELLSCAHFT (DE) 2002-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148423-A1 Process for Preparing (E)-(5,6-Dihydro-1,4,2-Dioxazine-3-YL) (2-Hydroxyphenyl) Methanone O-Methyl Oxime HMOX2, HAO2, HMOX1 MEN1 3281/4885KMT2A 470/4885STK17B 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.